U.S. markets open in 8 hours 36 minutes
  • S&P Futures

    3,835.75
    +26.50 (+0.70%)
     
  • Dow Futures

    31,100.00
    +188.00 (+0.61%)
     
  • Nasdaq Futures

    13,047.25
    +136.25 (+1.06%)
     
  • Russell 2000 Futures

    2,230.90
    +31.70 (+1.44%)
     
  • Crude Oil

    62.43
    +0.93 (+1.51%)
     
  • Gold

    1,748.20
    +19.40 (+1.12%)
     
  • Silver

    26.93
    +0.49 (+1.87%)
     
  • EUR/USD

    1.2090
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    1.4600
    0.0000 (0.00%)
     
  • Vix

    27.95
    -28.89 (-100.00%)
     
  • GBP/USD

    1.3978
    +0.0056 (+0.40%)
     
  • USD/JPY

    106.5380
    +0.0360 (+0.03%)
     
  • BTC-USD

    46,198.12
    +1,246.69 (+2.77%)
     
  • CMC Crypto 200

    922.91
    -10.23 (-1.10%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    29,584.91
    +618.90 (+2.14%)
     

Global Genetic Disorders Partnering Directory 2014-2020: Headline Value, Upfront Payment, Royalty Rate, Stage of Development at Signing, Deal Component Type, Technology Type, Therapy Indication

·4 min read

DUBLIN, Feb. 15, 2021 /PRNewswire/ -- The "Global Genetic Disorders Partnering 2014-2020: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo
Research and Markets Logo

Global Genetic Disorders Partnering 2014 to 2020 provides the full collection of Genetic Disorders disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Genetic Disorders disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Genetic Disorders deals.

The report presents financial deal terms values for Genetic Disorders deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The report also includes numerous tables and figures that illustrate the trends and activities in Genetic Disorders partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Genetic Disorders technologies and products.

Report scope

Global Genetic Disorders Partnering 2014 to 2020 includes:

  • Trends in Genetic Disorders dealmaking in the biopharma industry since 2014

  • Analysis of Genetic Disorders deal structure

  • Access to headline, upfront, milestone and royalty data

  • Access to hundreds of Genetic Disorders deal contract documents

  • Comprehensive access to over 530 Genetic Disorders deal records

  • The leading Genetic Disorders deals by value since 2014

  • Most active Genetic Disorders dealmakers since 2014

The report includes deals for the following indications: Cystic Fibrosis (CF), Down syndrome, Fragile X Syndrome, Hereditary angioedema, Huntington's disease, Rare genetic disorders, Neurofibromatosis, Sickle cell disease, plus other genetic indications.

In Global Genetic Disorders Partnering 2014 to 2020, available deals and contracts are listed by:

  • Headline value

  • Upfront payment value

  • Royalty rate value

  • Stage of development at signing

  • Deal component type

  • Technology type

  • Specific therapy indication

Key Topics Covered:

Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in Genetic Disorders dealmaking
2.1. Introduction
2.2. Genetic Disorders partnering over the years
2.3. Genetic Disorders partnering by deal type
2.4. Genetic Disorders partnering by industry sector
2.5. Genetic Disorders partnering by stage of development
2.6. Genetic Disorders partnering by technology type
2.7. Genetic Disorders partnering by therapeutic indication

Chapter 3 Financial deal terms for Genetic Disorders partnering
3.1. Introduction
3.2. Disclosed financials terms for Genetic Disorders partnering
3.3. Genetic Disorders partnering headline values
3.4. Genetic Disorders deal upfront payments
3.5. Genetic Disorders deal milestone payments
3.6. Genetic Disorders royalty rates

Chapter 4 Leading Genetic Disorders deals and dealmakers
4.1. Introduction
4.2. Most active in Genetic Disorders partnering
4.3. List of most active dealmakers in Genetic Disorders
4.4. Top Genetic Disorders deals by value

Chapter 5 Genetic Disorders contract document directory
5.1. Introduction
5.2. Genetic Disorders partnering deals where contract document available

Chapter 6 Genetic Disorders dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Genetic Disorders therapeutic target

Appendices

Appendix 1 Directory of Genetic Disorders deals by company A-Z 2014 to 2020
Appendix 2 Directory of Genetic Disorders deals by deal type 2014 to 2020
Appendix 3 Directory of Genetic Disorders deals by stage of development 2014 to 2020
Appendix 4 Directory of Genetic Disorders deals by technology type 2014 to 2020

For more information about this report visit https://www.researchandmarkets.com/r/650fpn


Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

Cision
Cision

View original content:http://www.prnewswire.com/news-releases/global-genetic-disorders-partnering-directory-2014-2020-headline-value-upfront-payment-royalty-rate-stage-of-development-at-signing-deal-component-type-technology-type-therapy-indication-301228166.html

SOURCE Research and Markets